However, another recent study (Tong et al., 2021) showed that both PD-1 and PD-L1 inhibitors significantly increase the risk of all-grade and high-grade pneumonia in NSCLC patients compared to conventional chemotherapy. This evidence concerns the gene CD274 and susceptibility to pneumonia measurement.